SMILES string
OC1=C(CC2=C(O)C(C(O)=O)=CC3=C2C=CC=C3)C4=C(C=CC=C4)C=C1C(O)=O.O=C([C@H](CC5)NC5=O)N[C@@H](CC6=CN=CN6)C(N[C@@H](CC7=CNC8=C7C=CC=C8)C(N[C@@H](CO)C(N[C@@H](CC9=CC=C(O)C=C9)C(N[C@H](CC%10=CNC%11=C%10C=CC=C%11)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N%12[C@H](
assay
≥95% (HPLC)
form
(Powder or lyophilized powder or film)
mol wt
1311.45 g/mol
storage condition
desiccated
color
white to off-white
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Synthetic LHRH agonist analog
Triptorelin pamoate is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It is used clinically to treat prostate cancer and precocious puberty in boys and girls.
Disclaimer
Hygroscopic
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Giulia Marvaso et al.
Anticancer research, 38(5), 3139-3143 (2018-05-02)
Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB). A retrospective
Delphine Zenaty et al.
Hormone research in paediatrics, 86(3), 188-195 (2016-11-02)
To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). We
Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study
BMC Urology, 18(1), 23-23 (2018)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持